|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Differential mucin phenotypes and their significance in a variation of colorectal carcinoma显示文摘AIM: To investigate mucin expression profiles in colorectal carcinoma (CRC) histological subtypes with regard to clinicopathologic variables and prognosis. METHODS: Mucin (MUC)2 and MUC5AC expressions were assessed by immunohistochemistry for a total of 250 CRC cases that underwent surgical resection. CRCs included 63 well-to-moderately differentiated adenocar-cinomas (WMDAs), 91 poorly differentiated adenocarcinomas (PDAs), 81 mucinous adenocarcinoma (MUAs), and 15 signet-ring cell carcinomas (SRCCs). MUC2 and MUC5AC were scored as positive when ≥ 25% and ≥ 1% of cancer cells were stained positive, respectively. The human mutL homolog 1 and human mutS homolog 2 expressions were assessed by immunohistochemistry in PDAs to investigate mismatch-repair (MMR) status.Tumors that did not express either of these two were considered MMR-deficient. Results were analyzed for associations with clinicopathologic variables and the prognosis in individual histological CRC subtypes. RESULTS: MUC2-positive and MUC5AC-positive WMDA percentages were 49.2% and 30.2%, respectively. In contrast, MUC2-positive and MUC5AC-positive PDA percentages were 9.5% and 51.6%, respectively. MUC2 levels tended to decrease and MUC5AC levels tended to increase from WMDA to PDA. In 21 tumors comprising both adenoma and adenocarcinoma components in a single tumor (4 WMDAs, 7 PDAs, and 10 MUAs), MUC2 was significantly downregulated in PDA and MUC5AC was downregulated in PDA and MUA in the adenoma-carcinoma sequence. These results suggested that MUC2 levels might be associated with malignant potential and that MUC5AC expression was an early event in tumorigenesis. Despite worse prognoses than WMDA, high MUC2 expression levels were maintained in MUA (95.1%) and SRCC (71.5%), which suggested a pathogenesis for these subtypes distinct from that of WMDA. No significant associations were found between MUC2 expression and any clinicopathologic variables in any histological subtype. MUC5AC expression in PDA was closely associated with right-sided location (P = 0.017), absence of nodal metastasis (P = 0.010), low tumor node metastasis stage (P = 0.010), and MMR deficiency (P = 0.003). MUC2 expression in WMDA was a marginal prognostic factor for recurrence/metastasis-free survival (RFS) by univariate Cox analysis (P = 0.077) but not by multivariate Cox analysis (P = 0.161). MUC5AC expression in PDA was a significant prognostic factor for RFS by univariate Cox analysis (P = 0.007) but not by multivariate Cox analysis (P = 0.104). Kaplan-Meier curves and log-rank tests revealed that MUC2 expression was marginally associated with a better WMDA prognosis [P = 0.064 for RFS and P = 0.172 for overall survival (OS)] but not for PDA. In contrast, MUC5AC expression was significantly and marginally associated with a better PDA prognosis in terms of RFS and OS, respectively(P = 0.004 for RFS and P = 0.100 for OS), but not for WMDA and MUA. CONCLUSION: Mucin core protein expression profiles and clinical significance differ according to histological CRC subtypes. This may reflect different pathogeneses for these tumors. | Yasuo Imai Hidetsugu Yamagishi Kazunori Fukuda Yuko Ono Tohru Inoue Yoshihiko Ueda | 2013 | World Journal of Gastroenterology2013，19，25： | 14 |
| 2 | 运用免疫荧光法检测温热对于硼化合物细胞微分布影响显示文摘目的硼中子俘获疗法(BNCT)的有效性主要取决于硼-10元素在肿瘤细胞内的聚集。目前的硼检测手段仅限于分析肿瘤组织中硼的平均浓度,不能准确地评价硼化合物(BPA)在组织中的详细分布。先前研究证实温热处理可以提高放疗疗效,本研究通过免疫荧光法检测温热是否对BPA细胞内的微分布有影响。方法通过免疫荧光法分析硼化合物在肿瘤细胞中的分布以及温热对BPA分布的影响。在体外对人肺癌细胞株A549和人头颈部鳞状细胞癌细胞株SAS进行培养,并且加入BPA共培养1h。另外,A549细胞经温热处理1h后,利用抗BPA抗体通过免疫荧光法进行检测。免疫荧光强度通过图像分析软件进行分析。结果检测发现BPA主要聚集于细胞核周围,BPA免疫荧光的强度随着培养基中BPA浓度的增加而增强。尽管在26μg/ml浓度和13μg/ml浓度时,细胞免疫荧光的平均强度相近,但直方图分析发现26μg/ml时细胞主要向高荧光强度区域移动。经温热处理后,BPA在细胞中的分布没有明显增加。结论本研究利用免疫荧光法对BPA在细胞内的分布进行了分析,以上结果暗示温热对肿瘤细胞硼摄取的影响可能主要需要通过改善肿瘤循环、增加肿瘤内BPA的输送来实现。 | 刘勇 Kashino Genro 陈一瑋 Masunaga Shin-ichiro Suzuki Minoru Kinashi Yuko Kirihata Mitsunori Ono Koji | 2012 | 中华临床医师杂志(电子版)2012，6，10： | 3 |
| 3 | The influence of donor age on liver regeneration and hepatic progenitor cell populations显示文摘 | Yoshihiro Ono Shigeyuki Kawachi Tetsu Hayashida Masatoshi Wakui Minoru Tanabe Osamu Itano Hideaki Obara Masahiro Shinoda Taizo Hibi Go Oshima Noriyuki Tani Kisyo Mihara Yuko Kitagawa | 2011 | Surgery2011，，2： | 2 |
| 4 | Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma显示文摘 | Yohji Honda Tomoki Kimura Hiroshi Aikata Tomoki Kobayashi Takayuki Fukuhara Keiichi Masaki Takashi Nakahara Noriaki Naeshiro Atsushi Ono Daisuke Miyaki Yuko Nagaoki Tomokazu Kawaoka Shintaro Takaki Akira Hiramatsu Masaki Ishikawa Hideaki Kakizawa Masahiro | 2013 | J Gastroenterol Hepatol2013，，3： | 2 |
| 5 | Possible role of single-voxel 1H-MRS in differential diagnosis of suprasellar tumors显示文摘 | Mikhail F. Chernov Takakazu Kawamata Kosaku Amano Yuko Ono Takashi Suzuki Ryoichi Nakamura Yoshihiro Muragaki Hiroshi Iseki Osami Kubo Tomokatsu Hori Kintomo Takakura | 2009 | Journal of Neuro - Oncology2009，，2： | 1 |
| 6 | Proton MRS of the peritumoral brain显示文摘 | Mikhail F. Chernov Osami Kubo Motohiro Hayashi Masahiro Izawa Takashi Maruyama Masao Usukura Yuko Ono Tomokatsu Hori Kintomo Takakura | 2004 | Journal of the Neurological Sciences2004，，2： | 1 |
| 7 | 窄带成像内镜无法发现的食管浅表性鳞状细胞癌的特点显示文摘背景:窄带成像内镜(NBI)对包括高级别上皮内瘤变在内的浅表性食管鳞状细胞癌(SESCC)的检出率明显高于白光内镜。然而,一些SESCC不能被NBI检测到,却可通过卢戈液染色内镜(LCE)检测到;目前这些SESCC的特征尚不清楚。因此,本研究旨在阐明NBI无法检测到的SESCC的特征。方法:本研究纳入患有头颈或食管SCC或者有头颈或食管SCC病史的患者。首先使用NBI进行食管检查,然后使用LCE检查。使用NBI检查过程中对所有可疑的SESCC病灶以及使用LCE检查过程中对不规则形状和大于5 mm和/或粉红色的卢戈液染色不着色的病变(LVL)进行活检。对NBI下无法发现的SESCC进行统计分析。结果:在105例患者中,147个病灶病理诊断为SESCC,其中15例患者中的20个病灶在NBI下无法检测到;这些病灶的形态均为肉眼观察下的扁平型(0-IIb)。NBI无法检测到的和NBI检测到的病灶大小的中值均为15 mm(P=0.47)。多因素分析揭示了NBI下无法检测到的病灶的独立因素,如大量不规则形状LVL(比值比[OR]:4.94,95%置信区间[CI]:1.39–17.5,P<0.05)和病灶位于食管前壁(OR:4.99,95%CI:1.58–15.8,P<0.05)。结论:当病灶形态完全扁平、内镜下观察到许多不规则形状的LVL或者病灶位于食管前壁时,单独使用NBI检测SESCC具有挑战性。 | Shingo Ono Akira Dobashi Hiroto Furuhashi Akio Koizumi Hiroaki Matsui Yuko Hara Kazuki Sumiyama | 2021 | Gastroenterology Report2021，9，5： | 1 |
| 8 | Role of proton magnetic resonance spectroscopy in preoperative evaluation of patients with mesial temporal lobe epilepsy显示文摘 | Mikhail F. Chernov Taku Ochiai Yuko Ono Yoshihiro Muragaki Fumitaka Yamane Takaomi Taira Takashi Maruyama Masahiko Tanaka Hiroshi Iseki Osami Kubo Yoshikazu Okada Tomokatsu Hori Kintomo Takakura | 2009 | Journal of the Neurological Sciences2009，，1： | 1 |
| 9 | Multivoxel proton MRS for differentiation of radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases显示文摘 | Mikhail F. Chernov Motohiro Hayashi Masahiro Izawa Masao Usukura Shimetoshi Yoshida Yuko Ono Yoshihiro Muragaki Osami Kubo Tomokatsu Hori Kintomo Takakura | 2006 | Brain Tumor Pathology2006，，1： | 1 |
| 10 | Comparison of ^1 H - MRS - detected metabolic characteristics in single metastatic brain tumors of different origin显示文摘 | Mikhail F Chemov Yuko Ono | 2006 | Brain Tumor Patho12006，23，1： | 1 |
| 11 | Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture显示文摘BACKGROUND Angiogenesis inhibitors(AIs)combination with cytotoxic chemotherapy is a promising treatment for patients with colorectal cancer(CRC).Aflibercept(AFL)is an option for second-line treatment of CRC,according to the‘VELOUR’trial.Currently,we can choose from three AIs,including bevacizumab,ramucirumab,and AFL.Different AIs can be used in subsequent treatment because of their distinctive mechanisms of action.We addressed the uncertainty regarding AFL efficacy and safety in heavily-treated patients by comparing outcomes of survival treatment with second-line treatment.AIM To determine and compare the efficacy and safety profiles of AFL in the secondline and salvage therapy settings.METHODS Clinical data of 41 patients with advanced CRC who received intravenous AFL combined with the folinic acid-fluorouracil-irinotecan(FOLFIRI)regimen were collected retrospectively from six institutions in Japan,for the period from May 2017 to March 2019.Patient characteristics collected included age,sex,tumor location,RAS and RAF status,metastatic sites,number of previous treatment cycles,therapeutic response,adverse events,duration of previous AI treatment,and survival time.The end points were time to AFL treatment failure(aTTF)and median survival time post-AFL(aMST).Statistical analyses were performed to compare the efficacy and safety in the second-line setting with those of the salvage therapy setting,which was defined as the days since the end of secondline therapy.RESULTS All 41 patients who received AFL+FOLFIRI for advanced CRC had metastatic or unresectable cancer.Twenty-two patients received AFL in the second-line setting and nineteen in the salvage therapy setting.The patient characteristics were similar in the two groups,except for two factors.The median duration of the previous AI administration was shorter in the second-line patients compared with that in the salvage therapy patients(144 d vs 323 d,P=0.006).In the second-line and salvage therapy groups,the objective response rates were 11%and 0%,respectively(P=0.50),and the disease control rates were 53%and 50%,respectively(P=1.00).In the second-line and salvage therapy groups,the aTTF(123 d vs 71 d,respectively),aMST(673 d vs 396 d,respectively),and incidence of adverse events of grade 3[8(36%)vs 9(47%)]were not significantly different between the two groups.CONCLUSION AFL can be used to treat advanced CRC patients,with a similar safety and efficacy in the salvage therapy setting as in the second-line setting. | Taichi Yoshida Kentaro Takahashi Kengo Shibuya Osamu Muto Yuko Yoshida Daiki Taguchi Kazuhiro Shimazu Koji Fukuda Fuminori Ono Kyoko Nomura Hiroyuki Shibata | 2021 | World Journal of Gastrointestinal Oncology2021，13，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员